Holen Sie sich die Stockscreener-App
8.72
0.68%
-0.06
Handel nachbörslich:
8.60
-0.12
-1.38%
Schlusskurs vom Vortag:
$8.78
Offen:
$8.72
24-Stunden-Volumen:
385.32K
Relative Volume:
0.93
Marktkapitalisierung:
$163.63M
Einnahmen:
$107.35M
Nettoeinkommen (Verlust:
$6.84M
KGV:
24.69
EPS:
0.3532
Netto-Cashflow:
$14.64M
1W Leistung:
+23.16%
1M Leistung:
+33.54%
6M Leistung:
-0.34%
1J Leistung:
-50.43%
1-Tages-Spanne:
$8.4505
$9.08
1-Wochen-Bereich:
$6.568
$9.08
52-Wochen-Spanne:
$4.54
$22.25
Optimizerx Corp Stock (OPRX) Company Profile
Firmenname
Optimizerx Corp
Sektor
Branche
Telefon
248-651-6558
Adresse
260 CHARLES STREET, WALTHAM, MI
Compare OPRX vs VEEV, BTSG, TEM, HQY, TXG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
8.72 | 132.11M | 107.35M | 6.84M | 14.64M | 0.3532 |
VEEV
Veeva Systems Inc
|
243.75 | 39.23B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
61.71 | 11.81B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
52.10 | 9.85B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
104.73 | 8.82B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
56.09 | 7.52B | 638.78M | -22.66M | 122.18M | -0.1744 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-07-25 | Fortgesetzt | B. Riley Securities | Buy |
| 2024-04-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-02-02 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-11-01 | Eingeleitet | Stifel | Buy |
| 2022-07-15 | Eingeleitet | SVB Leerink | Outperform |
| 2021-10-18 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-01-03 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Optimizerx Corp Aktie (OPRX) Neueste Nachrichten
OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital - Stock Titan
OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Citizens Jmp Analyst Says - MarketBeat
Citizens raises OptimizeRx stock price target on macro stability - Investing.com
Citizens raises OptimizeRx stock price target on macro stability By Investing.com - Investing.com Canada
Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx (OPRX) Fiscal Q2 2026 Earnings Call: Guidance Reaffirmed as Revenue Falls 30% - TradingKey
OptimizeRx Reaffirms 2026 Outlook Amid Revenue Decline - The Globe and Mail
OptimizeRx (OPRX) revenue falls 21% as margins and cash flow hold - Stock Titan
Stifel cuts OptimizeRx stock price target on revenue headwinds - Investing.com
OPTIMIZERx earnings beat by $0.06, revenue topped estimates - Investing.com Nigeria
OptimizeRx Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ... - Yahoo! Finance Canada
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Technology Magazine
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth - Technology Magazine
OptimizeRx Q2 Earnings Call Highlights - MarketBeat
OPRX Looks 45.1% Undervalued on GF Value™ - GuruFocus
OptimizeRx Q2 adj. EPS beats estimate as sales fall 30% YoY - scanx.trade
Earnings call transcript: OptimizeRx beats Q2 2026 profit view as shares slip - Investing.com Australia
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
OptimizeRx (NASDAQ:OPRX) Announces Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
OptimizeRx Latest Results: FY2026 sales guidance affirmed at $95M-$100M - scanx.trade
OptimizeRx names Andy D’Silva as CFO, Heather Favazza as CAO By Investing.com - Investing.com UK
OptimizeRx (OPRX) Q2 2026 revenue falls 30% but company reaffirms full-year outlook - Stock Titan
OptimizeRx CFO Ed Stelmakh Will Advise Through End of 2027 - Stock Titan
OptimizeRx Refinances Debt With $35M Facility, Pays Down $8.3M - Stock Titan
OptimizeRx Set to Report Q2 2026 Results With Analyst Targets Pointing to Over 80% Upside - finance.biggo.com
Earnings To Watch: OptimizeRx Corp (OPRX) Q2 2026 -- GF Value Sees 106% Upside - Yahoo Finance
OptimizeRx Corp (OPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OPRX News | OPTIMIZERX CORP (NASDAQ:OPRX) - ChartMill
OptimizeRx Corp (OPRX) Stock News Today - TradingKey
OPRX|OptimizeRx Corp|Price:7.080|Chg%:+0.340 - TradingKey
Segall Bryant & Hamill LLC Invests $1.19 Million in OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
OptimizeRx Corp (OPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET - The Manila Times
OptimizeRx Corp (OPRX) Cash Flow - TradingKey
OptimizeRx Corp (OPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OPRX|OptimizeRx Corp|Price:6.375|Chg%:+0.135 - TradingKey
OptimizeRx Corp (OPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
OptimizeRx Corp (OPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OptimizeRx Corp (OPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OptimizeRx Corp (OPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
OptimizeRx Corp (OPRX) Income Statement - TradingKey
OptimizeRx Corp (OPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OptimizeRx appoints Sarah Bast as chief marketing officer By Investing.com - Investing.com Nigeria
OptimizeRx appoints Sarah Bast as chief marketing officer - Investing.com
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer - The Manila Times
Press Release: OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer - Moomoo
Royce & Associates (OPRX) discloses 1.09M-share passive stake in OptimizeRx - Stock Titan
Mariyamma Varghese Presti Net Worth (2026) - GuruFocus
Finanzdaten der Optimizerx Corp-Aktie (OPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
6.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):